ANALYSIS: Measuring R&D success and myth
This article was originally published in Scrip
Who has been the best Big Pharma research and development (R&D) chief in the pharmaceutical industry recently? Those interested in the industry likely have found themselves asking this question. Often, it is argued that it is difficult to make an apples-to-apples judgment due to long development timelines, or different market climates.
Register for our free email digests: